HOME ·

GENFLEET-B

GENFLEET-B (02595.HK): buyback reaches 2,907,800 H shares
Tags：
GENFLEET-B02595.HKShare Buyback
2026-11-09
GENFLEET-B (02595.HK): GFH276 Combo Trials Cleared in China and Australia
Tags：
GENFLEET-B02595.HKinnovative drug
2026-11-04
GENFLEET-B (02595.HK): First Clinical Data for Pan-RAS Inhibitor GFH276 Selected as ESMO LBA
Tags：
NewTimeSpaceGENFLEET-B02595.HK
2026-10-26
GENFLEET-B (02595.HK): Oral KRAS G12D Inhibitor Advances, 44% ORR in CRC Combo and 41% cORR in PDAC
Tags：
GENFLEET-B02595.HKinnovative drug
2026-10-15
GENFLEET-B (02595.HK): GFH276 Data Selected as ESMO Late-Breaking Abstract
Tags：
GENFLEET-B02595.HKNewTimeSpace
2026-09-23
GENFLEET-B (02595.HK): GFH375 Combo Proposed for BTD in Colorectal Cancer
Tags：
GENFLEET-B02595.HKNewTimeSpace
2026-09-22
GENFLEET-B (02595.HK): Repurchases 872,000 H shares, about 0.227% of issued share capital
Tags：
GENFLEET-B02595.HKShare Repurchase
2026-09-21
GENFLEET-B (02595.HK): Phase II Data of GFH375 in Treated NSCLC Presented at WCLC, Confirmed ORR 52.1%
Tags：
NewTimeSpaceGENFLEET-B02595.HK
2026-09-15
GENFLEET-B (02595.HK): two first-in-class pancreatic cancer combination therapies of GFH375 advance to Phase II studies
Tags：
GENFLEET-B02595.HKClinical Trial
2026-08-20
GENFLEET-B (02595.HK): Phase III study of world's first oral KRAS G12D inhibitor for NSCLC initiated; second registrational clinical study of GFH375 completes first patient enrolment
Tags：
GENFLEET-B02595.HKR&D Progress
2026-08-10
GENFLEET-B (02595.HK) plans to issue in total 13.6 million shares by placement, with estimated net proceeds of HKD 466.9 million
Tags：
GENFLEET-B02595.HKshare placement
2026-07-15
GENFLEET-B(02595.HK) closed 9.28% higher, the Hang Seng Pharmaceuticals & Biotechnology Sector saw divergent trends
Tags：
GENFLEET-B02595.HK
2026-04-24